Total spending for cancer care in the U.S. has been reported to be about $125 billion in 2010 and is projected to increase to between 27% and 39% by 2020. A cancer diagnosis translates into significant spending that may continue for years for both payers and patients. This report characterizes the costs to cancer patients and their health plans for three cancers: breast, lung, and colorectal.
This report was commissioned by Pfizer, Inc.
Article
Given the greater flexibility and lower costs provided under ARPA’s provisions, plan sponsors should seize this moment to reevaluate and optimize their risk management strategies by considering the whole picture.